1 / 10

MULTITARGET DOCKING WITH DYNAMICS

MULTITARGET DOCKING WITH DYNAMICS. COMPOUND SELECTION. Compound database (~300,000). Multiple disease related proteins. DRUG-LIKE (~5000 from FDA). Compound library. Computational docking with dynamics. High throughput screen. Computational docking.

lel
Download Presentation

MULTITARGET DOCKING WITH DYNAMICS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MULTITARGET DOCKING WITH DYNAMICS COMPOUND SELECTION Compound database (~300,000) Multiple disease related proteins DRUG-LIKE (~5000 from FDA) Compound library Computational docking with dynamics High throughput screen Computational docking Experimental verificationSuccess rate +Time .Cost $$$$$ Initial candidates Initial candidates Experimental verificationSuccess rate ++Time .Cost $$$ Experimental verificationSuccess rate +++++Time .Cost $ Disease &target identification NOVEL FRAGMENT BASED TRADITIONAL SINGLE MULTITARGET SCREENING TARGET SCREENING Single disease related protein

  2. SHOTGUN MULTITARGET DOCKING WITH DYNAMICS ALL KNOWN DRUGS (~5,000 FROM FDA) FRAGMENT BASED DOCKING WITH DYNAMICS (~50,000,000) PRIORITISED HITS DISSOCIATION CONSTANTS (KD) (~300-500) + ALL TARGETS WITH KNOWN STRUCTURE (~5,000-10,000) IN VITRO STUDIES INITIAL CLINICAL TRIALS IN VIVO STUDIES CLINICAL STUDIES/APPLICATION

  3. DENGUE INHIBITOR DISCOVERY prediction #1 Costin, Jenwitheesuk, …, Samudrala, Michael, PLoS Negl Trop Dis, 2010

  4. MALARIA INHIBITOR DISCOVERY Predicted inhibitory constant 10-13 10-12 10-11 10-10 10-9 10-8 10-7 None Jenwitheesuk, Horst, Rivas, Van Voorhis, Samudrala, Trends in Pharm Sci, 2008

  5. Horst, Laurenzi, Samudrala, PolyPharmacology Hoffmann-La Roche, 2011

  6. G-protein coupled receptor A2α adenosine receptor 2.1 Å CαRMSD (CASP GPCR/3eml) Horst, Roy, Bernard, Zhang, Samudrala, in: Michino et al., Nat Rev Drug Disco, 2009

  7. G-protein coupled Receptor A2a Horst, Roy, Bernard, Iyer

  8. What MFS can do

  9. What MFS can do • How clear • can it be? Ornithine Decarboxylase+Pyridoxal-5’-PO4 (1ord) Wang, Horst, Cheng, Nickle, Samudrala, PLoS CompBio, 2008

  10. PROTEIN INHIBITOR DOCKING WITH DYNAMICS 1.0 0.5 with MD without MD Correlation coefficient ps 0 0.2 0.4 0.6 0.8 1.0 MD simulation time HIV protease Jenwitheesuk & Samudrala, AIDS, 2005

More Related